Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism-Reference-Cited by-同舟云学术

Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism

Published:2016-09 Issue:9 Volume:34 Page:1778-1786
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:

Author:

Verheyen Nicolas,Fahrleitner-Pammer Astrid,Pieske Burkert,Meinitzer Andreas,Belyavskiy Evgeny,Wetzel Julia,Gaksch Martin,Grübler Martin R.,Catena Cristiana,Sechi Leonardo A.,Van Ballegooijen Adriana J.,Brandenburg Vincent M.,Scharnagl Hubert,Perl Sabine,Brussee Helmut,März Winfried,Pilz Stefan,Tomaschitz Andreas

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Reference43 articles.

1. Hyperparathyroidism;Fraser;Lancet,2009

2. Calcium regulates FGF-23 expression in bone;David;Endocrinology,2013

3. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism;Kawata;J Am Soc Nephrol,2007

4. Calcium modulation of the renin-aldosterone axis;Porter;J Endocrinol Invest,1999

5. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell;Isales;Endocrinology,1991

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between primary hyperparathyroidism and cardiovascular outcomes: A systematic review and meta-analysis;Bone;2024-08

2. Linea guida sulla gestione terapeutica dell’iperparatiroidismo primario sporadico nell’adulto;L'Endocrinologo;2024-03-13

3. Italian Guidelines for the Management of Sporadic Primary Hyperparathyroidism;Endocrine, Metabolic & Immune Disorders - Drug Targets;2023-12-14

4. Improvement of hypertension control and left-ventricular function after cure of primary hyperparathyroidism;Frontiers in Endocrinology;2023-07-10

5. Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo‐controlled randomized trial;Clinical Endocrinology;2022-11-08